Oak Therapeutics and KU Medical Center cooperate on NIH-funded research

Together with Kansas University Medical Center, Oak Therapeutics will contribute to improving infant antiretroviral therapy (ART). One of the aims of the joint project 1R21HD105534-01 titled "Assessing caregiver and child preferences for the development of novel pediatric antiretroviral therapy”, funded by the National Institutes of Health (NIH) is to design a patient-centered approach to the development of an Oral Dissolvable Strip (ODS) for the treatment of HIV in infants and children.

Featured Posts
Recent Posts
Archive